Biological response modifiers BRMs

Biologic response modifiers (BRMs) are indicated in patients who have failed an adequate trial of DMARD therapy.1 BRMs may be added to DMARD monotherapy (i.e., methotrexate) or replace ineffective DMARD therapy.22 The decision to select a particular agent generally is based on the prescriber s comfort level with monitoring the safety and efficacy of the medications, the frequency and route of administration, the patient s comfort level or manual dexterity to self-administer subcutaneous injections, the cost, and the availability of insurance coverage.23 In general, BRMs should be avoided in patients with serious infections, demyelinating disorders (e.g., multiple sclerosis or optic neuritis) or heart failure.21... 

Natural and Synthetic Biological Response Modifiers (BRMs).159... 

NATURAL AND SYNTHETIC BIOLOGICAL RESPONSE MODIFIERS (BRMs)... 

TNF-a this is still an important disease target, and a number of dmgs are now on the market. In fact, these biological response modifiers (BRMs), directed towards... 

Recently, NCI has established a "disease-oriented" approach to antitumor activity screening [5,15,16], the biological response modifiers (BRM) [17,18] program, which takes into account the diversity and specificity of tumor, and the requirements of novel structure types and novel action-mechanistic types of anticancer agents. 

DHA-inserted phospholipids themselves have been receiving attention for their boosting effects on cell differentiators such as retinoic acid and dibutyryl cyclic adenosine monophosphate (2,3). For this reason, we intended to encapsulate a biological response modifier (BRM) in DHA-insert phospholipid liposomes, expecting that the DHA-inserted phospholipid bilayer of the liposomes might enhance the function of the BRM. 

IL-2 has been approved for the heatment of renal cell carcinoma and also has shown good activity in malignant melanoma. Both of these tumors are refractory to chemotherapy. IL-2 has also been used invesdgationally, both alone and in combinadon with LAK cells, with chemotherapy and with other biological response modifier s (BRM s) to d eat a variety of different cancers (e.g., head and neck carcinoma, colorectal cancer, cend al nervous system cancer etc). In addidon to cancer therapy, IL-2 has been used to d eat padents infected with human immunodeficiency virus and it has been used ex vivo to generate antiviral T cells which were reinfused into padents (Lewko and Oldham, 2003 Dorr, 1993). 

---